Axitinib is under clinical development by Clearside BioMedical and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase II drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Axitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Axitinib is under development for the treatment of choroidal neovascularization and wet age-related macular degeneration. The drug candidate is administered in suprachoroidal space through a micro needle. The drug candidate target both VEGF and PDGF. It is being developed based on SCS platform technology.
Clearside BioMedical overview
Clearside BioMedical (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise of CLS-AX, XIPERE and SCS Microinjector. Clearside’s proprietary suprachoroidal treatment approach offers unprecedented access to the back of the eye where sight threatening disease often occurs. The company also offers services such as business development, license agreements and contract manufacturing services. Clearside has partners with various pharmaceutical companies for the commercialization and development of its products across the US, Canada, China, Hong Kong, Macau, Taiwan and South Korea, among others. It markets its products across the US. Clearside is headquartered in Alpharetta, Georgia, the US.
For a complete picture of Axitinib’s drug-specific PTSR and LoA scores, buy the report here.